Contineum Therapeutics Sees Unusually High Options Volume (NASDAQ:CTNM)

Contineum Therapeutics, Inc. (NASDAQ:CTNM) saw some unusual options trading on Tuesday. Investors bought 10,034 call options on the company. This represents an increase of 4,420% compared to the typical volume of 222 call options.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CTNM shares. Robert W. Baird cut their price objective on shares of Contineum Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday. Royal Bank Of Canada raised their price objective on Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Finally, JonesTrading lowered their price objective on Contineum Therapeutics from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.80.

Contineum Therapeutics Stock Performance

NASDAQ CTNM traded down $1.52 on Tuesday, reaching $13.30. The company’s stock had a trading volume of 339,944 shares, compared to its average volume of 325,277. The firm’s 50 day moving average is $15.36 and its two-hundred day moving average is $14.05. The stock has a market cap of $500.46 million, a PE ratio of -7.69 and a beta of 0.75. Contineum Therapeutics has a twelve month low of $8.60 and a twelve month high of $17.78.

Contineum Therapeutics (NASDAQ:CTNM) last announced its earnings results on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. Equities research analysts anticipate that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

Contineum Therapeutics News Summary

Here are the key news stories impacting Contineum Therapeutics this week:

• Positive Sentiment: JonesTrading maintained a “buy” rating while lowering its price target from $26 to $24, implying substantial upside from recent levels. JonesTrading price target update
• Positive Sentiment: Investors purchased 10,034 CTNM call options, roughly 44 times the typical volume of 222 contracts. The unusually high call activity may signal speculative bullish interest, although options trading does not guarantee a sustained recovery.
• Positive Sentiment: Robert W. Baird retained an “outperform” rating and set a $19 price target, despite reducing its target from $20, indicating that the firm still sees meaningful value in Contineum’s broader pipeline.
• Negative Sentiment: The company reported that MOONLIGHT-1 did not achieve its primary endpoint, which measured the change in MADRS depression scores at Day 5 versus placebo. The disappointing result weakens the near-term investment case and may increase uncertainty around the drug candidate’s development path. Contineum Therapeutics Phase 2 results
• Negative Sentiment: Reports tied the stock’s decline to the failed major depressive disorder trial, suggesting investors are repricing the company’s clinical and commercial prospects following the readout. MOONLIGHT-1 trial misses primary endpoint

Hedge Funds Weigh In On Contineum Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP lifted its position in shares of Contineum Therapeutics by 123.8% in the second quarter. Seven Fleet Capital Management LP now owns 60,541 shares of the company’s stock worth $992,000 after buying an additional 33,487 shares during the last quarter. Wellington Management Group LLP increased its position in Contineum Therapeutics by 171.2% in the 2nd quarter. Wellington Management Group LLP now owns 150,797 shares of the company’s stock worth $2,472,000 after buying an additional 95,188 shares during the period. Bank of America Corp DE raised its stake in Contineum Therapeutics by 411.9% during the 1st quarter. Bank of America Corp DE now owns 47,449 shares of the company’s stock valued at $620,000 after purchasing an additional 38,180 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Contineum Therapeutics by 11.7% during the first quarter. Janus Henderson Group PLC now owns 2,734,836 shares of the company’s stock valued at $35,594,000 after buying an additional 285,857 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in Contineum Therapeutics by 73.5% in the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after acquiring an additional 2,454 shares in the last quarter.

About Contineum Therapeutics

Contineum Therapeutics, formerly known as Pipeline Therapeutics, is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for diseases of the central nervous system. The company’s research is aimed at promoting remyelination and neurorepair, processes that may restore damaged nerve function rather than solely managing disease symptoms.

Contineum’s lead programs include PIPE-307, an oral, brain-penetrant therapy designed to promote remyelination through selective inhibition of the M1 muscarinic receptor, and PIPE-791, an oral antagonist of the lysophosphatidic acid receptor 1.